UnknownPhase 1NCT05596266

CD5 CAR-T Therapy for Refractory/Relapsed CD5+ T-cell Acute Lymphoblastic Leukemia

Studying Acute lymphoblastic leukemia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Xuanwu Hospital, Beijing
Principal Investigator
Zhiguo Chen, PhD
Xuanwu Hospital, Beijing
Intervention
CD5 CAR-T(biological)
Enrollment
20 enrolled
Eligibility
1-18 years · All sexes
Timeline
20222025

Study locations (1)

Collaborators

Baoding Children's Hospital

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05596266 on ClinicalTrials.gov

Other trials for Acute lymphoblastic leukemia

Additional recruiting or active studies for the same condition.

See all trials for Acute lymphoblastic leukemia

← Back to all trials